ClinicalTrials.gg
CompletedNCT02100644Updated Nov 17, 2017Results posted

Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study

A Phase 4 interventional study of Lamotrigine tablets 25/100 mg in Epilepsy, sponsored by GlaxoSmithKline. Completed at 7 sites in Japan. Open to female participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
15 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Epilepsy by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Epilepsy · GlaxoSmithKline.

Enrollment
26th of 39
33 · median 76
Started
2014
with 1 other
Phase 4
5 of 54
none open now
Registered
54th of 54
by date

Among the 54 studies in Epilepsy by GlaxoSmithKline, this one is the 26th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 4, and was the 54th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 54 studies in Epilepsy by GlaxoSmithKline is open now. The open studies under Epilepsy, anywhere →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 15 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 54 studies in Epilepsy by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to examine whether the VPA (Valproate) dose can be reduced by additional administration of LTG (Lamotrigine) in Japanese pre-menopausal female epilepsy patients aged 15 years or older, whose seizures are well controlled by VPA monotherapy.

Read the detailed description

RATIONALE In several studies that investigated the effects of in utero exposure to AEDs (antiepileptic drugs) on fetal malformations and intellectual development in children after birth, it has been reported that VPA causes neonatal malformations and decreases intelligence of children in a dose dependent manner, whereas such a risk is low in LTG (Hernandez-Díaz et al., 2012; Meador et al., 2013). It has also been reported that LTG as adjunctive therapy with VPA is effective in inhibiting seizures in patients with poorly controlled seizures, and adverse events under VPA monotherapy can be relieved by subsequently reducing VPA dose after LTG is combined (Sale et al., 2005; Jozwiak et al., 2000; Morris et al, 2004; Buchanan, 1996). Thus, by considering the benefits of replacing VPA by LTG in childbearing women, we will examine whether VPA dose can be reduced by introducing LTG in Japanese female epilepsy patients under VPA monotherapy (aged ≥ 15 years, pre-menopausal).

STUDY DESIGN Single arm, multicenter, and open-label study TIME FRAME

  • Screening(Retrospective review of medical records for 12 weeks)
  • LTG escalation phase (8-18 weeks)
  • VPA reduction phase (3-16 weeks)
  • LTG \& VPA maintenance phase (12 weeks)
  • Follow up (1-4 weeks) PRIMARY OBJECTIVE To examine whether the VPA dose can be reduced by additional administration of LTG (up to 200 mg/d if there are no safety concerns) in Japanese pre-menopausal female epilepsy patients aged 15 years or older, whose seizures are well controlled by VPA monotherapy (fixed maintenance dose of 400-1200 mg/d).

SECONDARY OBJECTIVES

  • To investigate the steady state concentration of LTG immediately before VPA dose reduction, at the time of VPA dose reduction, and during the LTG\&VPA maintenance phase.
  • To investigate the safety and tolerability associated with additional administration of LTG followed by dose reduction of VPA.
03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (Target disease) Epilepsy patients having the following seizure types as classified by the International Classification of Epileptic Seizures

    • Partial seizures (with or without secondary generalization)
    • Tonic-clonic seizures with or without myoclonus but without other generalized seizure type(s)
  2. Subjects having a confident diagnosis of epilepsy that is uncomplicated by pseudoseizures such as psychogenic nonepileptic seizures
  3. Subjects whose seizures have been controlled for 12 weeks prior to start of the product with a stable maintenance dose of VPA monotherapy (400-1200 mg/d)
  4. (Age and gender)

Japanese pre-menopausal women who are at least 15 years old at the time of consent, not lactating, and can agree to use any of the following types of in a reliable fashion:

  1. Complete abstinence during the study as well as for a period after the study to account for elimination of the investigational product (a minimum of 2 weeks)
  2. Consistent and correct use of any of the following contraceptive methods

    • Surgical sterilization of male partner (i.e., male partner is the sole sexual partner for the female subject and is sterilized prior to the subject's entry into the study)
    • Intrauterine device with a failure rate of less than 1% per year
    • Double barrier method (e.g., spermicide plus a condom or a diaphragm) Note: Women who have had a hysterectomy or tubal ligation are considered to be of non-. Since a pharmacokinetic interaction has been observed between LTG and estrogen-based oral contraceptives, the use of hormonal therapy such as for contraception or hormone replacement therapy is not allowed.

      5.Outpatients 6.Subjects who can keep a seizure diary 7.Subjects who can understand and sign the . If the subject is under 20 years old at the time of consent, both the subject and subject's legally acceptable representative have to sign the consent to participate in the study.

      8. \<480 msec for subjects with bundle branch block or QTc \<450 msec for other subjects, in which QTc is measured by either single or triplicate-averaged 9.Subjects who can comply with dosing of the investigational and standard products and all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of to LTG
  2. Subjects with a history of rash associated with other AED treatments.
  3. Subjects who have received another AED besides VPA during the 12 weeks prior to start of the product
  4. Subjects with status epilepticus during the 6 months prior to start of the investigational product
  5. Subjects with a history of substance (including alcohol and drug) dependence or substance abuse as defined by the within 12 months or 1 month, respectively, prior to start of the investigational product
  6. Subjects with a severe acute or chronic illness likely to impair drug absorption, distribution, metabolism, or excretion; or subjects with any unstable physical symptom likely to require hospitalization during the study
  7. Subjects with a severe psychiatric disorder that affects the procedures of the study or drug assessment
  8. Subjects with an acute or progressive neurological disorder or an organic disease
  9. Subjects with any cardiac, renal, or hepatic medical condition. Any patient with these conditions will be excluded from the study even if these conditions are being controlled with a chronic therapy.
  10. Subjects with an unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Note: Chronic stable and C are acceptable if the subjects otherwise meet the inclusion criteria. However, the subjects with chronic stable hepatitis B will be excluded if significant agents are being administered due to a risk of hepatitis B reactivation.
  11. Subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study
  12. Subjects who are suspected to have an urea cycle disorder as below:

    • Subjects with a history of encephalopathy or coma of unknown cause
    • Subjects with a family history of infant death of unknown cause or urea cycle disorder
  13. Subjects taking inducers of LTG glucuronidation (i.e., rifampicinor lopinavir/ritonavir), atazanavir/ritonavir, risperidone, or oral or hormone drugs containing estrogen
  14. Subjects taking carbapenem antibiotic (i.e., panipenem/betamipron, meropenem hydrate, imipenem hydrate/cilastatin sodium, biapenem, doripenem hydrate, or tebipenem pivoxil)
  15. Subjects who have participated in other clinical studies within 3 months prior to start of the investigational product
  16. Subjects who have had active suicidal plans/intent or suicidal thoughts in the past 3 months prior to start of the investigational product; or subjects who have history of suicide attempts in the last 1 year prior to start of the investigational product or of multiple suicide attempts in their lifetime
  17. Subjects whom the investigator or subinvestigator considers ineligible for the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Lamotrigine

    The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.

    Drug: Lamotrigine tablets 25/100 mg

Interventions

  • DrugLamotrigine tablets 25/100 mg

    Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Reduction in Daily VPA Dose

    The VPA dose reduction from Baseline is defined as post VPA dose minus the Baseline VPA dose \< 0. Baseline VPA dose is the dose at the Baseline visit (Week 0) and the post VPA dose is the last VPA dose during the LTG and VPA Maintenance Phase. Percentage of participants with dose reduction during the LTG and VPA Maintenance Phase is presented.

    Time frame: Baseline and at the end of the LTG and VPA Maintenance Phase, 24-46 weeks that can be varied by durations of the LTG Escalation Phase and VPA Reduction Phase

  2. Percent Change in the VPA Dose

    Percent change in VPA dose is calculated as (pre-dose - post-dose) / pre-dose x 100. Pre-dose is the VPA dose at the Baseline visit and post-dose is the last VPA dose during the LTG and VPA Maintenance Phase.

    Time frame: Baseline and at the end of the LTG and VPA Maintenance Phase, 24-46 weeks that can be varied by durations of the LTG Escalation Phase and VPA Reduction Phase

Secondary outcomes

  1. Number of Days in Total That Epileptic Seizures Occurred up to the LTG and VPA Maintenance Phase

    The participants with no seizure, had no record in seizure dairy. Only those participants with more than one seizure were assessed for this Outcome Measure.

    Time frame: Baseline and up to 46 weeks

  2. Change From Baseline in Quality of Life in Epilepsy-31-P (QOLIE-31-P) in Participants Aged 18 Years and Older

    QOLIE-31-P is a questionnaire analyzed according to the scoring manual at Baseline, at the end of LTG/VPA Maintenance Phase and withdrawals for the participants aged 18 years and older (n=26, excluding 1 participant withdrawn due to protocol violation). Overall score was calculated as an average of sub scores that were normalized to 0 to 100. QOLIE-31-P has 7 subscale items (energy, mood, daily activities, cognition, medication effect, seizure worry and overall QOL). Higher score presents higher quality of life. Epileptic symptoms generally affect the QOL of participants, and so QOLIE-31-P is world widely used for the QOL assessment of adult participants. Baseline is defined as Day 1 (pre-dose) value. Change from Baseline is calculated as post-dose visit value minus Baseline value.

    Time frame: Baseline and up to 46 weeks

  3. Change From Baseline in Quality of Life in Epilepsy for Adolescents (QOLIE-AD-48) in Participants Aged 15-17 Years

    QOLIE-AD-48 is a questionnaire analyzed according to the scoring manual at Baseline, at the end of the LTG/VPA Maintenance Phase and withdrawals for participants aged 15-17 years (n=6). Particpants who has started by QOLIE-AD-48 were using the same questionnaire even after 18 years old. Overall score was calculated as an average of sub scores that were normalized to 0 to 100. QOLIE-AD-48 has 8 subscale items (epilepsy impact, memory/concentration, physical fuctioning, stigma, social support, school behavior, attitudes towards epilepsy and health perceptions). Higher score presents higher quality of life. Epileptic symptoms generally affect the QOL of participants, and so QOLIE-AD-48 is world widely used for the QOL assessment of non-adult participants. Baseline is defined as Day 1 (pre-dose) value. Change from Baseline is calculated as post-dose visit value minus Baseline value.

    Time frame: Baseline and up to 46 weeks

  4. Percentage of Participants Who Completed or Discontinued From the Study

    Following cases were considered for participants to have completed a part of or whole of the study. For whole period completion: participants who completed the last LTG and VPA Maintenance Phase visit (M5) in the LTG and VPA Maintenance Phase and follow-up examination. For LTG Escalation Phase completion: participants who reached 200 mg/d of LTG (or 100-200 mg/d of LTG if there were safety concerns) within 8-18 weeks of the phase. For VPA Reduction Phase completion: participants who completed the last fixed dose of VPA Reduction Phase visit (0 mg/d) (FR4) of the phase. For LTG and VPA Maintenance Phase completion: participants who completed M5 of the phase. Participants who met any of the withdrawal criteria after the start of investigational product were considered to have discontinued the study. Percentage of participants who completed or discontinued/withdrawn from the study is presented.

    Time frame: Up to 50 weeks

  5. Number of Participants With Adverse Events (AEs), AEs Leading to Discontinuation of the Investigational Product and/or Withdrawal From the Study, Drug-related AEs, Deaths and Serious Adverse Events (SAEs) Throughout the Study

    An AE is defined as untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgement and all events of possible drug-induced liver injury.

    Time frame: From the start of study treatment until follow-up (up to 50 weeks)

07

Results

Posted Feb 1, 2016

Participant flow

Participants (par.) receiving monotherapy treatment with sodium valproate (VPA) maintenance dose of 400-1200 milligrams/day \[mg/d\]) due to a history of partial seizures (including secondary generalized seizures) or tonic-clonic seizures, and whose seizures had been controlled for 12 weeks (wk) prior to start of treatment were enrolled in the study.

LTG Escalation Phase
Participant flow — LTG Escalation Phase
MilestoneEscalation Phase: LTG Plus VPAReduction Phase: LTG Plus VPAMaintenance Phase: LTG Plus VPA
Started3300
Completed2000
Not completed1300
Withdrew: Adverse event900
Withdrew: Protocol-defined stopping criteria100
Withdrew: Withdrawal by subject300
VPA Reduction Phase
Participant flow — VPA Reduction Phase
MilestoneEscalation Phase: LTG Plus VPAReduction Phase: LTG Plus VPAMaintenance Phase: LTG Plus VPA
Started0200
Completed0200
Not completed000
LTG and VPA Maintenance Phase
Participant flow — LTG and VPA Maintenance Phase
MilestoneEscalation Phase: LTG Plus VPAReduction Phase: LTG Plus VPAMaintenance Phase: LTG Plus VPA
Started0020
Completed0020
Not completed000

Outcome measures

PrimaryPercentage of Participants Who Achieved Reduction in Daily VPA Dose

The VPA dose reduction from Baseline is defined as post VPA dose minus the Baseline VPA dose \< 0. Baseline VPA dose is the dose at the Baseline visit (Week 0) and the post VPA dose is the last VPA dose during the LTG and VPA Maintenance Phase. Percentage of participants with dose reduction during the LTG and VPA Maintenance Phase is presented.

Time frame:
Baseline and at the end of the LTG and VPA Maintenance Phase, 24-46 weeks that can be varied by durations of the LTG Escalation Phase and VPA Reduction Phase
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Reduction in Daily VPA Dose
Percentage of participantsLTG Plus VPA (Phase 1, 2 and 3)
Percentage of Participants Who Achieved Reduction in Daily VPA Dose60.6 (42.14 to 77.09)
PrimaryPercent Change in the VPA Dose

Percent change in VPA dose is calculated as (pre-dose - post-dose) / pre-dose x 100. Pre-dose is the VPA dose at the Baseline visit and post-dose is the last VPA dose during the LTG and VPA Maintenance Phase.

Time frame:
Baseline and at the end of the LTG and VPA Maintenance Phase, 24-46 weeks that can be varied by durations of the LTG Escalation Phase and VPA Reduction Phase
Reported as:
Mean · Percentage of reduction
Percent Change in the VPA Dose
Percentage of reductionLTG Plus VPA (Phase 1, 2 and 3)
Percent Change in the VPA Dose-60.10 ± 49.290
SecondaryNumber of Days in Total That Epileptic Seizures Occurred up to the LTG and VPA Maintenance Phase

The participants with no seizure, had no record in seizure dairy. Only those participants with more than one seizure were assessed for this Outcome Measure.

Time frame:
Baseline and up to 46 weeks
Reported as:
Number · Days
Number of Days in Total That Epileptic Seizures Occurred up to the LTG and VPA Maintenance Phase
DaysLTG Plus VPA (Phase 1, 2 and 3)
Number of Days in Total That Epileptic Seizures Occurred up to the LTG and VPA Maintenance Phase2
SecondaryChange From Baseline in Quality of Life in Epilepsy-31-P (QOLIE-31-P) in Participants Aged 18 Years and Older

QOLIE-31-P is a questionnaire analyzed according to the scoring manual at Baseline, at the end of LTG/VPA Maintenance Phase and withdrawals for the participants aged 18 years and older (n=26, excluding 1 participant withdrawn due to protocol violation). Overall score was calculated as an average of sub scores that were normalized to 0 to 100. QOLIE-31-P has 7 subscale items (energy, mood, daily activities, cognition, medication effect, seizure worry and overall QOL). Higher score presents higher quality of life. Epileptic symptoms generally affect the QOL of participants, and so QOLIE-31-P is world widely used for the QOL assessment of adult participants. Baseline is defined as Day 1 (pre-dose) value. Change from Baseline is calculated as post-dose visit value minus Baseline value.

Time frame:
Baseline and up to 46 weeks
Reported as:
Mean · Scores on a scale
Change From Baseline in Quality of Life in Epilepsy-31-P (QOLIE-31-P) in Participants Aged 18 Years and Older
Scores on a scaleLTG Plus VPA (Phase 1, 2 and 3)
LTG Escalation-Withdrawal, n=10-7.19 ± 7.531
LTG and VPA Maintenance-Visit 5, n=160.19 ± 9.082
SecondaryChange From Baseline in Quality of Life in Epilepsy for Adolescents (QOLIE-AD-48) in Participants Aged 15-17 Years

QOLIE-AD-48 is a questionnaire analyzed according to the scoring manual at Baseline, at the end of the LTG/VPA Maintenance Phase and withdrawals for participants aged 15-17 years (n=6). Particpants who has started by QOLIE-AD-48 were using the same questionnaire even after 18 years old. Overall score was calculated as an average of sub scores that were normalized to 0 to 100. QOLIE-AD-48 has 8 subscale items (epilepsy impact, memory/concentration, physical fuctioning, stigma, social support, school behavior, attitudes towards epilepsy and health perceptions). Higher score presents higher quality of life. Epileptic symptoms generally affect the QOL of participants, and so QOLIE-AD-48 is world widely used for the QOL assessment of non-adult participants. Baseline is defined as Day 1 (pre-dose) value. Change from Baseline is calculated as post-dose visit value minus Baseline value.

Time frame:
Baseline and up to 46 weeks
Reported as:
Mean · Units on a scale
Change From Baseline in Quality of Life in Epilepsy for Adolescents (QOLIE-AD-48) in Participants Aged 15-17 Years
Units on a scaleLTG Plus VPA (Phase 1, 2 and 3)
LTG Escalation-Withdrawal, n=2-10.83 ± 11.862
LTG and VPA Maintenance-Visit 5, n=4-2.67 ± 6.356
SecondaryPercentage of Participants Who Completed or Discontinued From the Study

Following cases were considered for participants to have completed a part of or whole of the study. For whole period completion: participants who completed the last LTG and VPA Maintenance Phase visit (M5) in the LTG and VPA Maintenance Phase and follow-up examination. For LTG Escalation Phase completion: participants who reached 200 mg/d of LTG (or 100-200 mg/d of LTG if there were safety concerns) within 8-18 weeks of the phase. For VPA Reduction Phase completion: participants who completed the last fixed dose of VPA Reduction Phase visit (0 mg/d) (FR4) of the phase. For LTG and VPA Maintenance Phase completion: participants who completed M5 of the phase. Participants who met any of the withdrawal criteria after the start of investigational product were considered to have discontinued the study. Percentage of participants who completed or discontinued/withdrawn from the study is presented.

Time frame:
Up to 50 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Completed or Discontinued From the Study
Percentage of participantsLTG Plus VPA (Phase 1, 2 and 3)
Completed61
Withdrawn39
SecondaryNumber of Participants With Adverse Events (AEs), AEs Leading to Discontinuation of the Investigational Product and/or Withdrawal From the Study, Drug-related AEs, Deaths and Serious Adverse Events (SAEs) Throughout the Study

An AE is defined as untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgement and all events of possible drug-induced liver injury.

Time frame:
From the start of study treatment until follow-up (up to 50 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs), AEs Leading to Discontinuation of the Investigational Product and/or Withdrawal From the Study, Drug-related AEs, Deaths and Serious Adverse Events (SAEs) Throughout the Study
ParticipantsLTG Plus VPA (Phase 1, 2 and 3)
Any AEs30
Drug-related AEs17
Any SAEs4
AEs leading to discontinuation/withdrawal9
AEs leading to death0

Adverse events

Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from the start of study treatment and until the follow-up contact (up to 50 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LTG Plus VPA (Phase 1, 2 and 3)—4/33 (12.1%)23/33 (69.7%)
Most frequent serious events
Most frequent serious events
EventLTG Plus VPA (Phase 1, 2 and 3)
Drug eruptionSkin and subcutaneous tissue disorders3/33
Histiocytic necrotising lymphadenitisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/33
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLTG Plus VPA (Phase 1, 2 and 3)
NasopharyngitisInfections and infestations9/33
SomnolenceNervous system disorders5/33
RashSkin and subcutaneous tissue disorders5/33
GastroenteritisInfections and infestations4/33
InfluenzaInfections and infestations3/33
DizzinessNervous system disorders3/33
HeadacheNervous system disorders3/33
PyrexiaGeneral disorders3/33
TremorNervous system disorders2/33
Drug eruptionSkin and subcutaneous tissue disorders2/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)LTG Plus VPA (Phase 1, 2 and 3)
Mean25.6 ± 7.73
Sex: Female, Male
Sex: Female, Male(Participants)LTG Plus VPA (Phase 1, 2 and 3)
Female33
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LTG Plus VPA (Phase 1, 2 and 3)
Asian- Japanese Heritage33
08

Study locations

7 sites
  • GSK Investigational Site
    Hyogo, 664-8540, Japan
  • GSK Investigational Site
    Kagoshima, 892-0844, Japan
  • GSK Investigational Site
    Kyoto, 606-8507, Japan
  • GSK Investigational Site
    Osaka, 560-8565, Japan
  • GSK Investigational Site
    Saitama, 351-8551, Japan
  • GSK Investigational Site
    Shizuoka, 430-8558, Japan
  • GSK Investigational Site
    Tokyo, 185-0012, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in May 2015, 12 months.

Results were first posted in Feb 2016, 8 months after primary completion.

Of 43 phase 4 interventional studies under Epilepsy, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2014
First posted
Apr 1, 2014
StartActual
Apr 12, 2014
Primary completionActual
May 11, 2015
CompletionActual
May 11, 2015
Results first posted
Feb 1, 2016
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02100644
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 1, 2014
Start date
Apr 12, 2014
Primary completion
May 11, 2015
Completion
May 11, 2015
Results posted
Feb 1, 2016
Last update
Nov 17, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion